… In conclusion, F90 has potent anti-tumor activity on human lung cancer in vitro and … anti-tumor
activity of a novel quinazoline-based compound F90 as an EGFR tyrosine kinase inhibitor …

… Since the purpose of this review is to discuss HER-2 therapeutics, an extensive assessment
of EGFR inhibitors is beyond its scope. However, given the similarity in the kinase domains …

… and the molecular effects of gefitinib EGFR inhibition on downstream signal proteins by …
between EGFR gene copy number, EGFR gene mutations, and gefitinib sensitivity. EGFR protein …

… , herein, we describe the design and synthesis of two series of 4-aminoquinoline and
aminoquinazoline derivatives as possible antitumor agents that may act through EGFR inhibition. …

… IMO, cetuximab and another EGFR antagonist, on EGFR and a set of … Finally, we have
evaluated the antitumor activity of IMO in … a relevant activity in colorectal cancer patients (22, 23). …

… examined the antitumor effect of a newly synthesized novel EGFR tyrosine kinase inhibitor
(… In conclusion, Zhao260054 has potent antitumor activity on human lung cancer in vitro and …

… Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer
… active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that …

… , as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and … inhibits
both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR …

… of EGFR inhibitors that are approved for treatment of EGFR-… antitumor activity as afatinib
in this cell line (Figure 1B). To test whether ibrutinib can elicit in vivo antitumor activity in EGFR-…

… EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR
inhibitors, and current standard of care for NSCLC patients with EGFR Ex20Ins is conventional …